NDA 202211 · Abbvie
Oxytrol For Women
Oxybutynin · Transdermal · Cholinergic Muscarinic Antagonist
Last checked: Nov 20, 2026Latest source record: Mar 3, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Jan 25, 2013
Approved uses
1
Original approval plus efficacy supplements
Registered trials
103
25 Phase 3, 9 recruiting
FAERS reports
28,263
13,571 serious, 1,688 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 15, 2024.
Use treats overactive bladder in women you may be suffering from overactive bladder if you have had 2 or more of the following symptoms for at least 3 months: ○ urinary frequency (the need to urinate more often than usual; typically more than 8 times in 24 hours) ○ urinary urgency (a strong need to urinate right away) ○ urge incontinence (leaking or wetting yourself if you cannot control the urge to urinate) non-drug therapies may also help you (see the consumer information leaflet inside the package)
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jan 25, 2013 Original approval · Type 8 - Partial Rx to OTC Switch LabelReviewSummary Review
1 products under this application
- OXYTROL FOR WOMEN · OXYBUTYNIN 3.9MG/24HR · FILM, EXTENDED RELEASE, TRANSDERMAL · Over-the-counter
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxybutynin" as an intervention, any sponsor and status, largest first.
- Transdermal (TDS) Oxybutynin (Oxytrol(r)) in Overactive BladderPivotal-lookingCompleted
Watson PharmaceuticalsIndustry
NCT00224146 · 2,878 participants · Start May 2004 · Primary completion May 2005
Drug: oxybutynin transdermal delivery system (Oxytrol(r)) · For: Overactive Bladder; Urinary Incontinence; Quality of Life
Sites: Mobile, Alabama; Tucson, Arizona; Torrance, California · 10 sites in all
- A Comparative Effectiveness Study of Positive Airway Pressure (PAP) Therapy, Dental Device, and Atomoxetine-Oxybutynin for Treatment of Obstructive Sleep Apnea in AdultsPivotal-lookingRecruiting
Sairam ParthasarathyAcademic, hospital or other
NCT07679282 · 2,400 participants (planned) · Start Sep 4, 2026 · Primary completion Mar 1, 2030
Drug: Atomoxetine-oxybutynin · For: Obstructive Sleep Apnea (OSA)
Sites: Tucson, Arizona; Redwood City, California; Miami, Florida · 4 sites in all
- Study to Gather Information About the Actual Use of an Adhesive Patch Placed on the Skin to Deliver Oxytrol Through the Skin Into the Bloodstream.Pivotal-lookingCompleted
BayerBayer (BAYRY)
NCT04534491 · 855 participants · Start May 25, 2010 · Primary completion Jun 22, 2011
Drug: Oxybutynin (Oxytrol, BAY839380) · For: Overactive Bladder
Sites: Saint Joseph, Missouri
- Efficacy and Tolerability of DITROPAN XL (Oxybutynin Chloride) Versus DETROL LA (Tolterodine Tartrate) in Treatment of Overactive BladderPivotal-lookingCompleted
Alza Corporation, DE, USAIndustry
NCT00293839 · 790 participants
Drug: oxybutynin chloride · For: Urinary Incontinence
- A Comparison of a New Drug to Treat Overactive Bladder vs. PlaceboPivotal-lookingCompleted
Watson PharmaceuticalsIndustry
NCT00350636 · 789 participants · Start Jun 2006 · Primary completion May 2007
Drug: Oxybutynin topical gel · For: Overactive Bladder
Sites: Birmingham, Alabama; Homewood, Alabama; Mobile, Alabama · 63 sites in all
- Study of Topically Administered Oxybutynin Gel in Patients With Urge IncontinencePivotal-lookingCompleted
Antares Pharma Inc.Industry
NCT00909181 · 626 participants · Start Mar 2009 · Primary completion Jul 2010
Drug: Oxybutynin; Placebo · For: Urge Urinary Incontinence; Urinary Frequency
Sites: Birmingham, Alabama; Little Rock, Arkansas; Laguna Hills, California · 55 sites in all
- InSite for Over Active BladderPivotal-lookingCompleted
MedtronicNeuroIndustry
NCT00547378 · 571 participants · Start Oct 2007 · Primary completion Aug 2016
Drug: Standard Medical Therapy · For: Urinary Incontinence, Urgency-frequency; Overactive Bladder
- Desloratadine With Oxybutynin for the Treatment of Seasonal Allergic Rhinitis and Post-Nasal Drip (Study P04258)(COMPLETED)Pivotal-lookingCompleted
Organon and CoIndustry
NCT00816972 · 540 participants · Start Apr 2005 · Primary completion Jun 2005
Drug: Desloratadine 2.5 mg; Oxybutynin 2.5 mg and 2 more · For: Post-nasal Drip; Seasonal Allergic Rhinitis; Rhinorrhea
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- drug ineffective3,815
- fatigue1,549
- fall1,463
- off label use1,258
- nausea1,218
- dizziness1,122
- diarrhoea1,110
- pain1,071
- urinary tract infection1,045
- headache986
- pruritus950
- asthenia900
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 178 |
| 2005 | 196 |
| 2006 | 150 |
| 2007 | 43 |
| 2008 | 55 |
| 2009 | 90 |
| 2010 | 345 |
| 2011 | 572 |
| 2012 | 725 |
| 2013 | 1,492 |
| 2014 | 5,252 |
| 2015 | 2,300 |
| 2016 | 1,799 |
| 2017 | 1,880 |
| 2018 | 2,030 |
| 2019 | 2,054 |
| 2020 | 1,776 |
| 2021 | 1,500 |
| 2022 | 1,477 |
| 2023 | 1,350 |
| 2024 | 1,023 |
| 2025 | 1,144 |
| 2026 | 831 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Treatment of urge incontinence in postmenopausal women: A systematic review.
Bapir R, Bhatti KH, Eliwa A, et al. · Arch Ital Urol Androl 2023 · Meta-Analysis, Systematic Review
- Pharmacological treatment for obstructive sleep apnea: A systematic review and meta-analysis.
Nobre ML, Sarmento ACA, de Oliveira PF, et al. · Clinics (Sao Paulo) 2024 · Meta-Analysis, Systematic Review
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2007 · Systematic Review
- Nocturnal enuresis.
Kiddoo D · BMJ Clin Evid 2011 · Systematic Review
- Comparative assessment of efficacy and safety of approved oral therapies for overactive bladder: a systematic review and network meta-analysis.
He W, Huang G, Cui W, et al. · Int Braz J Urol 2023 · Systematic Review, Network Meta-Analysis
- A muscarinic receptor antagonist reverses multiple indices of diabetic peripheral neuropathy: preclinical and clinical studies using oxybutynin.
Casselini CM, Parson HK, Frizzi KE, et al. · Acta Neuropathol 2024 · Randomized Controlled Trial, Research Support, N.I.H., Extramural
Sponsor: AbbVie
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.